The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 23, 2024

Filed:

Dec. 16, 2022
Applicant:

Centivax, Inc., South San Francisco, CA (US);

Inventor:

Jacob E. Glanville, San Francisco, CA (US);

Assignee:

CENTIVAX, INC., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/155 (2006.01); A61K 35/76 (2015.01); A61K 38/46 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/21 (2006.01); A61K 39/245 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); G16B 20/30 (2019.01); G16B 30/00 (2019.01); G16B 30/10 (2019.01); G16B 35/00 (2019.01); G16B 35/10 (2019.01); G16C 20/60 (2019.01); G16B 20/00 (2019.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 38/46 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/21 (2013.01); C12N 7/00 (2013.01); G16B 20/30 (2019.02); G16B 30/00 (2019.02); G16B 30/10 (2019.02); G16B 35/00 (2019.02); G16B 35/10 (2019.02); G16C 20/60 (2019.02); A61K 2039/515 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/53 (2013.01); A61K 2039/575 (2013.01); A61K 2039/70 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16071 (2013.01); C12N 2740/16122 (2013.01); C12N 2740/16134 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/16134 (2013.01); C12Y 306/05002 (2013.01); G16B 20/00 (2019.02);
Abstract

The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a 'design process' comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.


Find Patent Forward Citations

Loading…